Ras Proteins News and Research

RSS

Revolutionary therapeutic shows promise for pancreatic cancer treatment

A new type of investigational therapeutic in development for pancreatic cancer has shown unprecedented tumor-fighting abilities in preclinical models of the disease, suggesting it has the potential to offer novel treatment options for nearly all pancreatic tumors, a comprehensive study has found.

8 Apr 2024

Discovery about cell membrane 'blebs' could lead to new ways to fight melanoma

Cell membrane protrusions called blebs that typically signify the end of life for healthy cells do the opposite for melanoma cells, activating processes in these cells that help them to survive and spread, a UT Southwestern study suggests.

3 Mar 2023

Scientific breakthrough by Sjöberg laureate brings new hope to lung cancer patients

This year's Sjöberg Prize in cancer research of one million dollars is awarded to professor Kevan Shokat, University of California, USA.

15 Feb 2023

UNIGE scientists develop a novel tool to visualize palmitoylation process in living cells

Peripheral membrane proteins have the particularity of temporarily binding to cell membranes, a necessary step for them to be able to fulfil their biological function.

26 Apr 2022

Researchers reveal new therapeutic way to block oncogenic RAS mutants

As a 10-year journey comes to fruition, MUSC Hollings Cancer Center researcher John O'Bryan, Ph.D., and colleagues have demonstrated a new therapeutic way to block a protein that is frequently mutated in cancers.

9 Feb 2022

Multiscale model reveals the importance of lipids to the signaling dynamics of RAS proteins

Lawrence Livermore National Laboratory researchers and a multi-institutional team of scientists have developed a highly detailed, machine learning-backed multiscale model revealing the importance of lipids to the signaling dynamics of RAS, a family of proteins whose mutations are linked to numerous cancers.

10 Jan 2022

CSHL researchers discover how pancreatic cancer cells develop resistance to drug treatments

Cancer cells can become resistant to treatments through adaptation, making them notoriously tricky to defeat and highly lethal. Cold Spring Harbor Laboratory Cancer Center Director David Tuveson and his team investigated the basis of "adaptive resistance" common to pancreatic cancer.

22 Jun 2021

Researchers gain new insights into the structure of cancer-promoting Ras protein

Almost all attempts to use the Ras protein as a point of attack for medications have so far failed. New knowledge concerning its structure is raising hopes of options in the development of medications.

2 Jun 2021

Studies reveal the promise of newly engineered bispecific antibodies against tumor cells

Three studies - one each in Science, Science Translational Medicine, and Science Immunology - reveal the promise of newly engineered bispecific antibodies, including by demonstrating their power against previously inaccessible tumor cell targets for the first time, in two cases.

2 Mar 2021

Study shows how normal RAS interacts with mutated RAS in living cells

Many cancer medications fail to effectively target the most commonly mutated cancer genes in humans, called RAS.

19 May 2020

LLNL leads multi-institutional collaboration in modeling protein interactions linked to cancer

Computational scientists, biophysicists and statisticians from Lawrence Livermore National Laboratory and Los Alamos National Laboratory are leading a massive multi-institutional collaboration that has developed a machine learning-based simulation for next-generation supercomputers capable of modeling protein interactions and mutations that play a role in many forms of cancers.

31 Oct 2019

Peptide-based nanoparticles can suppress pancreatic cancer growth without adverse effects

Despite advances in cancer survival, more than 90 percent of people with pancreatic cancer die within five years. Most patients with pancreatic tumors (and half of those with colorectal cancers) carry a mutation in the KRAS gene, which normally controls cell growth and death.

21 Oct 2019

Breast cancer drugs could tackle lung cancers resistant to targeted therapies

A class of drugs used to treat certain breast cancers could help to tackle lung cancers that have become resistant to targeted therapies, suggests a new study in mice from the Francis Crick Institute and the Institute of Cancer Research.

27 Dec 2018

Study uncovers new mechanism controlling the master cancer regulator

Of the more than 23,000 genes in the human genome, only a handful assume a very central role in signal transduction and growth regulation. Of these, the three genes encoding RAS proteins are particularly important, as they are found mutated in over 25% of human cancers.

20 Nov 2018

Researchers identify LZTR1 as evolutionarily conserved component of RAS pathway

Mutations in RAS proteins initiate many of the most aggressive tumors, and the search for pharmacological inhibitors of these proteins has become a priority in the battle against cancer. Michail Steklov, Francesca Baietti, and colleagues from the Anna Sablina lab identified LZTR1 as an evolutionarily conserved component of the RAS pathway.

16 Nov 2018

Drug used to treat dizziness may slow down growth of triple-negative breast cancer

Screening Food and Drug Administration approved compounds for their ability to stop cancer growth in the lab led to the finding that the drug flunarizine can slow down the growth of triple-negative breast cancer in an animal model of the disease.

16 Nov 2018

New model could predict personalized waiting time for progression in colorectal cancer

An evolutionary model utilizing serial blood samples from patients with advanced colorectal cancer treated with anti-EGFR therapies in a phase II trial could predict personalized waiting time for progression.

30 Aug 2018

Researchers use 'top-down proteomics' strategy to get new insights into cancer

When a RAS gene operates normally, it acts as an on/off switch for cell signaling to control cell proliferation. But when the gene mutates, the switch jams into the "on" position, allowing cells to proliferate uncontrollably.

18 Apr 2018

Researchers discover potential hurdle for personalized medicine

A recent study has shown that loss of the Erk oncogene can stimulate tumorigenesis in cells where Ras has been eliminated. The findings may have important consequences for the development of personalized medicines that target Ras.

17 Apr 2018

Researchers uncover Ras protein's role in uncontrolled cancer growth

Protein systems, such as Ras, make up the complex signaling pathways that control whether a cell divides or, in some cases, becomes cancerous and metastasizes into other regions of the body. For example, 98 percent of pancreatic cancers show Ras protein mutations.

19 Feb 2018